Possibility of re-screening intervals of morethan one year in men with PSA levels of 4.0 ng/ml or less

被引:29
作者
Ito, K [1 ]
Yamamoto, T [1 ]
Ohi, M [1 ]
Takechi, H [1 ]
Kurokawa, K [1 ]
Suzuki, K [1 ]
Yamanaka, H [1 ]
机构
[1] Gunma Univ, Sch Med, Dept Urol, Maebashi, Gumma 3718511, Japan
关键词
screening interval; prostate cancer; PSA; PROSTATE-SPECIFIC ANTIGEN; DIGITAL RECTAL EXAMINATION; CANCER DETECTION; UPDATE;
D O I
10.1002/pros.10268
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND. The optimal re-screening interval is one of the most important issues to evaluate the effectiveness of screening for prostate cancer. METHODS. Between 1992 and 2000, 7,026 men aged 50-78 with baseline PSA levels of 4.0 ng/ml or lower underwent screening for prostate cancer twice or more. The risk of developing prostate cancer relative to elapsed years and baseline PSA levels were investigated. RESULTS. Prostate cancer was detected in a total of 127 cases (1.8%). The detection rate of prostate cancer was high between 1.6% and 5.5% at 1 year after baseline PSA measurements in men with baseline PSA levels of 2.1-4.0 ng/ml. In men with baseline PSA levels of 1.1-2.0 ng/ml, the detection rate increased from 0.06% to 1.02% with passed years. The proportion of stage greater than or equal toT3 was high at 63% in prostate cancer cases detected between 3 and 4 years after baseline PSA levels being 1.1-2.0 ng/ml. In men with baseline PSA levels of 1.0 or lower, the cumulative detection rate of prostate cancer was low at 0.01% within 3 years, however, the detection rate increased to 0.34% after 5 or more years from baseline PSA measurements. CONCLUSIONS. The re-screening interval was recommended to be 1, 1-2, and 3-5 years for men with baseline PSA levels of 2.1-4.0 ng/ml, 1.1-2.0 ng/ml, and 1.0 ng/ml or lower, respectively. (C) 2003 Wiley-Liss, Inc.
引用
收藏
页码:8 / 13
页数:6
相关论文
共 17 条
[1]  
[Anonymous], 2000, ONCOLOGY-BASEL, V14, P277
[2]  
[Anonymous], 2000, ONCOLOGY-BASEL, V14, P267
[3]   The incidence of prostate cancer in a screening population with a serum prostate specific antigen between 2.5 and 4.0 ng./ml.: Relation to biopsy strategy [J].
Babaian, RJ ;
Johnston, DA ;
Naccarato, W ;
Ayala, A ;
Bhadkamkar, VA ;
Fritsch, HA .
JOURNAL OF UROLOGY, 2001, 165 (03) :757-760
[4]   Digital rectal examination for detecting prostate cancer at prostate specific antigen levels of 4 ng/ml or less [J].
Carvalhal, GF ;
Smith, DS ;
Mager, DE ;
Ramos, C ;
Catalona, WJ .
JOURNAL OF UROLOGY, 1999, 161 (03) :835-839
[5]   Use of percentage of free prostate-specific antigen to identify men at high risk of prostate cancer when PSA levels are 2.51 to 4 ng/mL and digital rectal examination is not suspicious for prostate cancer: An alternative model [J].
Catalona, WJ ;
Partin, AW ;
Finlay, JA ;
Chan, DW ;
Rittenhouse, HG ;
Wolfert, RL ;
Woodrum, DL .
UROLOGY, 1999, 54 (02) :220-224
[6]  
Crawford D, 2002, J UROLOGY, V167, P99
[7]   Prostate cancer detection in black and white men with abnormal digital rectal examination and prostate specific antigen less than 4 ng./ml. [J].
Fowler, JE ;
Bigler, SA ;
Farabaugh, PB ;
Wilson, SS .
JOURNAL OF UROLOGY, 2000, 164 (06) :1961-1963
[8]   Usefulness of age-specific reference range of prostate-specific antigen for Japanese men older than 60 years in mass screening for prostate cancer [J].
Ito, K ;
Yamamoto, T ;
Kubota, Y ;
Suzuki, K ;
Fukabori, Y ;
Kurokawa, K ;
Yamanaka, H .
UROLOGY, 2000, 56 (02) :278-282
[9]  
Ito K, 2001, CANCER-AM CANCER SOC, V91, P744, DOI 10.1002/1097-0142(20010215)91:4<744::AID-CNCR1060>3.0.CO
[10]  
2-C